They are CD19 CAR-T cells used for the treatment of B-cell malignancies, BCMA CAR-T cells used for the treatment of multiple myeloma, and CD7 CAR-T cells used for the treatment of T-lymphocyte hematologic malignancies and some acute myeloid leukemia (AML). This evidence concerns the gene CD7 and hematologic disorder.